Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125
NCT ID: NCT02247323
Last Updated: 2021-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2016-01-31
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
NCT06182917
Ovarian Reserve After Cancer: Longitudinal Effects
NCT02467231
Ovarian Cancer Risk Estimation in Patients With Pelvic Mass
NCT00987649
Screening for Ovarian Malignancy
NCT06348784
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
premenopausal women
premenopausal women with complex ovarian mass moderate for malignancy by risk of malignancy index score and low CA125.
Risk of malignancy index
Calculation of RMI before sugery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risk of malignancy index
Calculation of RMI before sugery.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Abdominal pain
* Menometrorrhagia
Exclusion Criteria
* Cachexia
* History of ovarian or other malignancy
* Family history of ovarian Cancer
45 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nesreen Abdel Fattah Abdullah Shehata
Assistant Professor of Obstetrics and Gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nesreen A Shehata, MD
Role: PRINCIPAL_INVESTIGATOR
Beni-Suef University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beni-Suef University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Abdelgany M Hassan, MD
Role: backup
Related Links
Access external resources that provide additional context or updates about the study.
National Institute for health and clinical excellence. Ovarian cancer:The recognition and initial management of ovarian cancer.NICE clinical guideline 122.London:NICE;2011
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Beni-Suef 6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.